Zhang Rixin, Wang Chengye, Tian Yu, Yao Yifan, Mao Jiakai, Wang Haibo, Li Zhenghan, Xu Yakun, Ye Mingliang, Wang Liming
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Hospital of Dalian Medical University, NO.467, Zhongshan Road, Dalian, Liaoning 116023, China.
Department of Vascular Surgery, The Second Hospital of Dalian Medical University, NO.467, Zhongshan Road, Dalian, Liaoning 116023, China.
J Cancer. 2019 Jun 10;10(16):3871-3882. doi: 10.7150/jca.31266. eCollection 2019.
SIRT5 belongs to a family of NAD-dependent lysine deacetylases called sirtuins. Although accumulating evidence indicates SIRT5 upregulation in cancers, including liver cancer, the detailed roles and mechanisms remain to be revealed. Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths among men worldwide, and finding effective targets for HCC treatment and prevention is urgently needed. In the present study, we confirmed that mitochondrial sirtuins, particularly SIRT5, are more highly expressed in HCC cell lines than in normal liver cell lines. Moreover, SIRT5 knockdown suppresses HCC cell proliferation and SIRT5 overexpression promotes HCC cell proliferation. Furthermore, we verified that SIRT5 knockdown increases HCC cell apoptosis via the mitochondrial pathway. By co-IP and western blotting, we illustrated that SIRT5 deacetylates cytochrome c thus regulating HCC cell apoptosis. Taken together, our findings suggest that SIRT5 may function as a prognostic factor and drug target for HCC treatment.
SIRT5属于一类名为沉默调节蛋白的依赖烟酰胺腺嘌呤二核苷酸(NAD)的赖氨酸脱乙酰酶家族。尽管越来越多的证据表明SIRT5在包括肝癌在内的多种癌症中表达上调,但其具体作用和机制仍有待揭示。肝细胞癌(HCC)是全球男性癌症相关死亡的第二大主要原因,因此迫切需要找到有效的HCC治疗和预防靶点。在本研究中,我们证实线粒体沉默调节蛋白,尤其是SIRT5,在肝癌细胞系中的表达高于正常肝细胞系。此外,敲低SIRT5可抑制肝癌细胞增殖,而过表达SIRT5则促进肝癌细胞增殖。此外,我们还证实敲低SIRT5可通过线粒体途径增加肝癌细胞凋亡。通过免疫共沉淀和蛋白质印迹法,我们证明SIRT5使细胞色素c去乙酰化,从而调节肝癌细胞凋亡。综上所述,我们的研究结果表明SIRT5可能作为肝癌治疗的预后因素和药物靶点。